Ephrins as Novel Targets in Neuronal Regeneration
Summary Chemokines play an intrinsic role in immunity and neural trafficking through their interactions with GPCRs. A reverse signaling mechanism of Ephrin B/EphB receptor has been discovered to inhibit GPCR sensitivity to chemokine binding. Reduced GPCR sensitivity is mediated by a novel cytoplasmic protein, PDZ-RGS3. Results in a Xenopus adhesion assay indicate that attraction of the SDF-1 chemokine to its GPCR receptor, CXCR4 (BDNF), was inhibited by PDZ-RGS3 binding with Ephrin B. The invention provides novel evidence that G-proteins can be regulated through ephrins, and further, that the G-protein pathway can be modulated by extracellular signals acting through the PDZ-RGS3 protein.
Applications For Further Information Please Contact the Director of Business Development Katie Gordon Email:
[email protected] Telephone: (617) 432-0920
Inventor(s):
Flanagan, John G.
Type of Offer:
Licensing
« More Pharmaceutical Patents